JP2015514093A5 - - Google Patents

Download PDF

Info

Publication number
JP2015514093A5
JP2015514093A5 JP2015503582A JP2015503582A JP2015514093A5 JP 2015514093 A5 JP2015514093 A5 JP 2015514093A5 JP 2015503582 A JP2015503582 A JP 2015503582A JP 2015503582 A JP2015503582 A JP 2015503582A JP 2015514093 A5 JP2015514093 A5 JP 2015514093A5
Authority
JP
Japan
Prior art keywords
use according
administered
thymosin alpha
sepsis
alpha peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015503582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514093A (ja
Filing date
Publication date
Priority claimed from US13/835,107 external-priority patent/US20130296223A1/en
Application filed filed Critical
Publication of JP2015514093A publication Critical patent/JP2015514093A/ja
Publication of JP2015514093A5 publication Critical patent/JP2015514093A5/ja
Pending legal-status Critical Current

Links

JP2015503582A 2012-03-30 2013-03-28 敗血症の処置のためのチモシンαの使用 Pending JP2015514093A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261618563P 2012-03-30 2012-03-30
US61/618,563 2012-03-30
US201261643824P 2012-05-07 2012-05-07
US61/643,824 2012-05-07
US13/835,107 2013-03-15
US13/835,107 US20130296223A1 (en) 2012-03-30 2013-03-15 Use of thymosin alpha for the treatment of sepsis
PCT/US2013/034394 WO2013149030A2 (en) 2012-03-30 2013-03-28 Use of thymosin alpha for the treatment of sepsis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017108931A Division JP2017214377A (ja) 2012-03-30 2017-06-01 敗血症の処置のためのチモシンαの使用

Publications (2)

Publication Number Publication Date
JP2015514093A JP2015514093A (ja) 2015-05-18
JP2015514093A5 true JP2015514093A5 (enExample) 2015-12-17

Family

ID=49261395

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015503582A Pending JP2015514093A (ja) 2012-03-30 2013-03-28 敗血症の処置のためのチモシンαの使用
JP2017108931A Pending JP2017214377A (ja) 2012-03-30 2017-06-01 敗血症の処置のためのチモシンαの使用
JP2019120721A Pending JP2019156854A (ja) 2012-03-30 2019-06-28 敗血症の処置のためのチモシンαの使用
JP2021065044A Pending JP2021100983A (ja) 2012-03-30 2021-04-07 敗血症の処置のためのチモシンαの使用
JP2022161403A Pending JP2022176345A (ja) 2012-03-30 2022-10-06 敗血症の処置のためのチモシンαの使用
JP2025076491A Pending JP2025107346A (ja) 2012-03-30 2025-05-02 敗血症の処置のためのチモシンαの使用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017108931A Pending JP2017214377A (ja) 2012-03-30 2017-06-01 敗血症の処置のためのチモシンαの使用
JP2019120721A Pending JP2019156854A (ja) 2012-03-30 2019-06-28 敗血症の処置のためのチモシンαの使用
JP2021065044A Pending JP2021100983A (ja) 2012-03-30 2021-04-07 敗血症の処置のためのチモシンαの使用
JP2022161403A Pending JP2022176345A (ja) 2012-03-30 2022-10-06 敗血症の処置のためのチモシンαの使用
JP2025076491A Pending JP2025107346A (ja) 2012-03-30 2025-05-02 敗血症の処置のためのチモシンαの使用

Country Status (8)

Country Link
US (5) US20130296223A1 (enExample)
EP (2) EP2841088B1 (enExample)
JP (6) JP2015514093A (enExample)
KR (1) KR20150048663A (enExample)
CN (2) CN105338996A (enExample)
CA (1) CA2866435A1 (enExample)
HK (1) HK1246694A1 (enExample)
WO (1) WO2013149030A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023943A1 (en) * 2014-08-12 2016-02-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
WO2019028448A1 (en) * 2017-08-04 2019-02-07 The Johns Hopkins University APPLICATION FOR EARLY PREDICTION OF SEPTIC SHOCK WAITING
US11504071B2 (en) * 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
PT3781210T (pt) * 2018-04-20 2024-10-02 Combioxin Sa Tratamento da hipotensão com sépsis ou choque séptico
EP4370129A1 (en) 2021-07-12 2024-05-22 2N Pharma ApS Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
WO1995009647A1 (en) * 1993-10-07 1995-04-13 The George Washington University Medical Center METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN-α¿1?
TW252045B (enExample) * 1993-10-07 1995-07-21 Allan L Goldstein
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
UA80957C2 (en) 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
KR20050086819A (ko) * 2002-11-25 2005-08-30 시클론 파마수티컬 인코포레이티드 알파 티모신을 사용한 방사능 손상에 대한 보호방법
AU2006297289B2 (en) * 2005-09-29 2013-03-21 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
CN101020048A (zh) * 2007-02-12 2007-08-22 广东天普生化医药股份有限公司 一种用于治疗脓毒症的药物组合物
ES2427596T3 (es) * 2007-03-21 2013-10-31 Bausch & Lomb Incorporated Composiciones y métodos para tratar, reducir, mejorar, o prevenir infecciones causadas por bacterias resistentes a fármacos antibacterianos
WO2009075813A1 (en) * 2007-12-12 2009-06-18 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
CN101514228A (zh) * 2008-02-21 2009-08-26 张卓兵 N-端修饰的人胸腺肽α1复合物及其制备方法
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
EP2416800A1 (en) * 2010-02-25 2012-02-15 Agennix AG Oral lactoferrin in the treatment of severe sepsis
WO2012109106A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection

Similar Documents

Publication Publication Date Title
JP2016074740A5 (enExample)
Jackson et al. Aminoglycosides: how should we use them in the 21st century?
Stryjewski et al. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus
Ager et al. Clinical update on linezolid in the treatment of Gram-positive bacterial infections
Kumar An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy
Agrawal et al. Acute bacterial meningitis in infants and children: epidemiology and management
Melton‐Celsa et al. New therapeutic developments against Shiga toxin‐producing Escherichia coli
JP2015529225A5 (enExample)
JP2015518818A5 (enExample)
JP2017526627A5 (enExample)
RU2015132369A (ru) Комбинированная терапия для лечения нозокомиальной пневмонии
JP2007514749A5 (enExample)
JP2010222367A5 (enExample)
JP2016507547A5 (enExample)
FI3616695T3 (fi) Menetelmät keuhkojen sisäisten infektioiden hoitamiseksi
JP2013509389A5 (enExample)
JP2019511496A5 (enExample)
HK1205939A1 (en) Parenteral formulations for administering macrolide antibiotics
RU2016147048A (ru) Противомикробная иммуномодуляция
RU2018125622A (ru) Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза
JP2012525391A5 (enExample)
Segarra-Newnham et al. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia
CN107714678B (zh) 紫檀芪在制备mcr-1酶抑制剂中的应用
JP2017530142A5 (enExample)
JP2015533131A5 (enExample)